Owen Mumford Achieves B Corp Certification

Owen Mumford, a global leader in the design, manufacture, and advancement of medical devices, today announced it has been awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this hard-to-achieve, globally-recognized mark.

Owen Mumford, which established its sustainability program in 2014 and has formally committed to the UN’s Sustainable Development Goals (SDGs), now joins a highly respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.

B Corp is the standard for a new generation of aspirational brands who are helping to define the future of business in a responsible way. There are now 4,010 B Corps in 77 countries and 153 industries, and over 100,000 companies manage their impact with the B Impact Assessment and the SDG Action Manager. The B Corp community in the UK, representing a broad cross-section of industries and sizes, comprises over 400 companies.

B Corp certification assesses five areas of impact: governance, community, workers, environment and customers. “Our social and environmental responsibilities have always been high on the agenda at Owen Mumford,” said Jarl Severn, CEO at Owen Mumford. “Submitting ourselves to the rigorous process of B Corp certification is a natural development of our core principles. Companies like ours that operate in the medical sector are used to the demands of a tightly regulated environment. We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to achieving a recognized certification. After all, our marketplaces are reliant on top ethical standards to protect environments, professionals and patients. B Corp provides a solid benchmark for continually improving what we do in our business, in the global communities that we are part of and the ones where can make a positive impact.”

Owen Mumford has pioneered the design and manufacture of medical devices such as self-injection, blood sampling, and drug delivery for almost 70 years and is the first such company to become part of the B Corp community. This milestone firmly underscores its commitment to making a positive difference on social and environmental impact.

Kate Sandle, Director of Programmes and Engagement of B Lab UK, says “We are delighted to welcome Owen Mumford to the B Corp community. This is a movement of companies who are committed to changing how the business operates and believe business really can be a force for good. We know that Owen Mumford is going to be a fantastic addition to the community and will continue driving the conversation forward. Welcoming Owen Mumford is an exciting moment because it has an opportunity to lead the way within the medical device industry.”

B Corp certification must be renewed every three years to ensure continuing compliance to the stringent requirements.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version